Privacy Notice

Effective Date: October 29, 2020


Teva Pharmaceuticals USA, Inc. and its North American affiliates (collectively, "Teva”) is providing this notice (“Privacy Notice”) to explain our online information practices and the choices you can make about the way your information is collected and used. This Privacy Notice applies only to the use and collection of data collected by this website, and does not apply to any other data collected by Teva or its affiliates through any other website or other means.

As used in this Privacy Notice, "we," "our" and "us" means Teva, and its related companies and affiliates.

The Data We Collect

We collect and store information that you voluntarily choose to give us or enter on our website, such as personal identifiers (e.g., your name, address, email address, mobile number, and username and password (if any)), professional or employment-related information (e.g. professional title and credentials), and medical information and other health information that you provide during account registration or otherwise. If you do not want us to collect this information, please do not provide it to us.

We may also collect certain other categories of information automatically, including internet and electronic network activity information such as your device type, Internet Protocol (IP) address, device and advertising identifiers, operating system, Internet service provider, the date and time of your website use, information about the links you click and your other interactions with the website, and other standard log information. We also may receive error-reporting information in the event of a technical error, including the device type and version, device identifiers, the time the error occurred, the feature being used, the state of the website when the error occurred, and any communications or content provided at the time the error occurred.

We and our third party partners may use cookies, pixel tags and similar technologies to automatically collect and store any of the above information. Cookies are small bits of information that are stored by a web browser. Pixel tags are very small images or small pieces of data embedded in images, also known as “web beacons” or “clear GIFs,” that can recognize cookies, the time and date a page is viewed, a description of the page where the pixel tag is placed, and similar information from your device. By using the website, you consent to our and our third party partners’ use of cookies and similar technologies.

We also use Google Analytics, an analytics tool provided by Google, to collect and analyze information about your access and use of the website. This information is collected and processed by Google and may identify, for example, the name of the website, which parts of the site you visit, how you arrived at the website, the frequency and duration of those visits, how you navigate within the website, which elements of the website you interact with and other usage data. Google Analytics uses cookies and other identifiers to identify you each time you use the website. For more information about the data Google collects and how it uses that data, please visit www.google.com/policies/privacy/partners/.

Use and Sharing of Data

We may use the data we collect, including your personally identifiable information, for such business purposes as authentication, to provide you with services that you request, and/or to personalize product or service information for you. We may also use the data we collect, including your personally identifiable information, to provide you with additional information about our products and services, to provide you with advertising based on your activity on our websites and on third-party websites, to optimize or improve our products, services and operations (including the effectiveness of our promotional or advertising campaigns), to manage customer information across Teva websites, apps and other platforms and to detect, investigate and prevent activities that may violate our policies or be illegal, or for technical support, troubleshooting or account administration purposes.

We may also share your personally identifiable information with our affiliates, agents, contractors, or trusted business partners in order that they may perform services for us. Our agents, contractors, or trusted business partners may use your information consistent with their own privacy notices.

We may also share your personally identifying information with third parties (i) as required by law, (ii) to protect and defend the rights of Teva, the website, or the users of the website, (iii) as incident to a corporate sale, merger, reorganization, dissolution, bankruptcy, or similar event, (iv) under circumstances we believe reasonably necessary to protect the personal safety of users of Teva products and services, the website or the public, or (v) as specifically directed by you.

We will share your personal information with third parties only in the ways that are described in this Privacy Notice. We do not sell your personal information to third parties.

We also may collect information from other sources and combine it with information we collect about you under this Privacy Notice. We may analyze, make inferences, and conduct research on users’ demographics, interests and behaviors based upon information provided to us during their use of our website or that we have otherwise obtained and combined with your information. We also may produce anonymous, aggregated statistical information. Aggregated data does not include personally identifiable information. We use this demographic information, such as the percentage of male or female visitors, or the percentage of visitors within certain age brackets, to gain user insights or improve the content of our website. We also may share this anonymous, aggregated information, which does not include personally identifiable information and is not subject to this Privacy Notice, with third parties.

Safety, Efficacy, and Quality

You consent to our use and disclosure of your personal information in the event we become aware of an adverse event or product complaint in order to (a) comply with any reporting requirements under applicable law, and (b) contact you for further information about the adverse event or product complaint. Click here to access Teva’s Global Pharmacovigilance Privacy Policy and learn how we collect and use personal data to help us fulfill our pharmacovigilance obligations.

Public Forums

You should also be aware that any communication you submit or that may be posted to any publicly viewable interactive feature such as a blog, community forum or testimonial page is a public communication and may be viewed by the general public. Therefore, you should not expect privacy or confidentiality of the content you submit to such services over our websites, whether or not it includes personal information about you. If you display your personal information in any communication submitted to such services or features, other individuals may collect and use your personal information. We are not responsible for, nor can we guarantee the protection of, any personal information you disclose in a communication submitted to such services or features for posting or contained in an email or other communication submitted to us for such posting, and thus, if you disclose personal information in any such material, you do so at your own risk.

Testimonials

From time to time, we display personal testimonials on our website in addition to other endorsements. With your consent we may post your testimonial along with your name. If you wish to update or delete your testimonial, you can contact us at USPrivacy@tevapharm.com.

Communications

We may collect your contact information through the website to provide you product, safety or service information or other requested information or services. By providing your contact information to us, you consent to receive electronic communications, including email communications, from Teva regarding the website and other related matters. If you subscribe to a newsletter(s) or request other product or service information, we will use your contact information to send such information to you. You may choose to stop receiving our newsletter or marketing emails by following the unsubscribe instructions included in these emails, accessing the email preferences in your account settings page or you can contact us at USPrivacy@tevapharm.com.

On some websites, if you choose to use our referral function to tell a friend about our website, we will ask you for your friend's name and e-mail address as well as your information. The form automatically sends your friend a one-time email inviting him or her to visit the website. We will only collect and use this information to send this invitation.

Surveys

We may provide you the opportunity to participate in surveys on our website. If you participate, we will request certain personally identifiable information from you. Participation in these surveys is completely voluntary and you therefore have a choice whether or not to disclose this information. The requested information typically includes contact information (such as name and email address), and demographic information and/or health information (such as zip code and health condition information).

Social Media Features

Our website may include social media features, such as the Facebook “Like” button and Widgets, the “Share this” button, and interactive mini-programs that run on our website. These Features may collect identifiers such as your IP address, internet and electronic network activity information such as which page you are visiting on our website, and may set a cookie to enable the feature to function properly. Social Media features and widgets are either hosted by a third party or hosted directly on our website. Your interactions with these features are governed by the Privacy Notice of the company providing it. In addition, if you use social media or other third-party services (e.g., Facebook or Google) to login to the website, these third parties may be able to collect information about you in accordance with their own privacy notices. We do not control the privacy practices of these third parties, and you should review their privacy notices carefully.

Protecting Your Information

We have enacted commercially reasonable physical, technical, and administrative safeguards to secure your information that is stored on our systems. You should understand, however, that no data storage system or transmission of data over the Internet or any other public network can be guaranteed to be 100 percent secure.

Special Note Regarding Website Use by Children

We do not knowingly collect or solicit personal information from anyone under the age of 13. This website is not intended or designed to attract children. If you are under 13, please do not send any personal information about yourself to us. If you believe that we might have any information from or about a child under 13, please contact us at USPrivacy@tevapharm.com and we will delete such information.

Links to Other Websites and Access to Third Party Services

As a resource to our visitors, we may provide links to other websites or access to third party services (TPS) that we do not own or control. Please be aware that these other resources are not covered under this Privacy Notice. We suggest that when linking to another website or accessing a TPS, you always read that website's privacy notice before volunteering any personally identifiable information.

For example, this website uses YouTube API services, and when engaging YouTube content through the website you are subject to the YouTube Terms of Service (https://www.youtube.com/t/terms), Privacy Policy (https://policies.google.com/privacy), and API Services Terms of Service (https://developers.google.com/youtube/terms/api-services-terms-of-service).

Location Services

Some services on this website may make use of location-based data. If you allow these services, we may collect information about the Wi-Fi routers closest to you or the cell IDs of the towers closest to you. We may use this information to provide the requested service or to provide you content based upon your location. Although we may use or collect geolocation data, we are not capable of assisting in an emergency.

"Refer-A-Friend" or “Forward-to-a-Friend” Functionality

We may offer you opportunities to request that we send content from our website or otherwise reach out to friends or family members that you believe may be interested in learning more about our products or services. If you choose to make such a referral, which is voluntary, we may ask you for your name and contact information as well as contact information for the individual or individuals that you refer, such as their name, email address and/or phone number. When we contact your friend, we may identify you as the party that made the referral.

Online Tracking and Opt-Out Options

We work with third party advertising or personalization partners that use tracking pixels or cookies to help us display personalized content and advertising based on your visits to this website or other websites, and across your devices. Cookies placed by our third party partners may also assist us with measuring the performance of our advertising campaigns. Some of these third parties permit you to opt-out of cookies and interest-based advertising through the Network Advertising Initiative (https://www.networkadvertising.org/consumer/opt_out.asp) and Digital Advertising Alliance (https://www.aboutads.info/choices/).

Do Not Track (DNT) is a preference you can set in your web browser to let the websites you visit know that you do not want to be tracked. You can disable or enable this setting by visiting the Preferences or Settings menu of your web browser. This website does not respond to do not track (DNT) signals.

Changes to this Privacy Notice

Teva may, from time to time in its sole discretion, change or modify this Privacy Notice to accommodate new technologies, industry practices, regulatory requirements or for other purposes. Any changes or modifications will be effective upon posting of the revisions on the website. At any given time, your access and use of the website and provision of information is governed by the Privacy Notice then in effect. We may post changes or modifications to referenced policies and guidelines without your approval, and may determine whether and when any such changes apply to you. Your continued use of the website following our posting of any changes or modifications will constitute your acceptance of such changes or modifications. Should you not wish to be bound by the modified Privacy Notice, you may not use or access the website. We will provide notice to you if these changes are material and, where required by applicable law, we will obtain your consent.

Feedback

Comments, suggestions, or other communications sent by you to us are deemed to be non-confidential. We have no obligations of any kind in relation to such comments, suggestions, or communications and are free to use or distribute them in any way, including in relation to the administration, update, or improvement of the website, without compensation to the author, sender, or any other party.

By using the website, you signify your assent to this Privacy Notice. Should you have any questions or concerns regarding this Privacy Notice you may contact us at:

Notice to California Residents – Your California Privacy Rights

This section supplements the description of our information collection and sharing practices elsewhere in this Privacy Notice to provide certain disclosures to California residents whose personal information Teva processes pursuant to the California Consumer Privacy Act (“CCPA”). Please note that these disclosures do not apply to information that is not processed under the CCPA.

During the preceding 12 months, Teva has collected, used, and shared the categories of personal information described above in this Privacy Notice. For example, depending on the Services you use, this may include identifiers (e.g., email addresses, IP addresses, and mobile device identifiers), health information, demographic information, geolocation information, and internet or other electronic network activity information. This may also include inferences we draw from the other information we collect. See the “The Data We Collect,” “Surveys,” “Location Services” and other relevant sections of this Privacy Notice for more details.

Under the CCPA, California residents may have the request that a business that collects consumers’ personal information give consumers additional transparency and access to the specific pieces of personal information that the business has collected about the consumer. California residents also have the right to submit a request for deletion of information under certain circumstances. Please note that these rights are not absolute. For example, we may not delete information we are required to retain for regulatory reasons, certain internal business purposes, or where otherwise provided for by law. In addition, we will not respond to a request if we cannot verify you as the requestor.

Once we receive your request, we may verify it by requesting information sufficient to confirm your identity, including by asking you for additional information. If you would like to use an agent registered with the California Secretary of State to exercise your rights, we may request evidence that you have provided such agent with power of attorney or that the agent otherwise has valid written authority to submit requests to exercise rights on your behalf.

Consistent with California law, if you choose to exercise your rights, we will not charge you different prices or provide different quality of services unless those differences are related to your information or otherwise permitted by law. Please submit your request by sending an email to USPrivacy@tevapharm.com or by telephone at 1-800-545-8800.

Indications and Important Safety Information for ProAir Digihaler

INDICATIONS FOR PROAIR DIGIHALER

INDICATIONS

ProAir® Digihaler®
 (albuterol sulfate) Inhalation Powder is indicated in patients ≥4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients ≥4 years of age for the prevention of exercise-induced bronchospasm.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

  • Contraindications: ProAir Digihaler (albuterol sulfate) Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose
  • Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs
  • Deterioration of Asthma: Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids
  • Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids
  • Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
  • Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
  • Immediate Hypersensitivity Reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.
  • Coexisting Conditions: ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.
  • Hypokalemia: As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation
  • Adverse Reactions: In controlled studies in patients 12 years of age and older, adverse events that occurred in ≥1% and >placebo included back pain (2% vs 1%), pain (2% vs <1%), gastroenteritis viral (1% vs <1%), sinus headache (1% vs <1%), and urinary tract infection (1% vs <1%). In controlled studies in patients 4 to 11 years of age, adverse events that occurred in ≥2% and >placebo included nasopharyngitis (2% vs 1%), oropharyngeal pain (2% vs 1%), and vomiting (3% vs 1%)
  • Drug Interactions: Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler
    • Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers
    • Diuretics: Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels
    • Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler
    • Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

Please read the full Prescribing Information for ProAir Digihaler.

Indications And Important Safety Information for Armonair Digihaler and AirDuo Digihaler

INDICATIONS FOR AIRDUO DIGIHALER AND
ARMONAIR DIGIHALER

INDICATIONS

ArmonAir® Digihaler® (fluticasone propionate) inhalation powder is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

Important Limitation of Use: ArmonAir Digihaler is NOT indicated for the relief of acute bronchospasm.

AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder is indicated for the treatment of asthma in patients aged 12 years and older. AirDuo Digihaler is only for patients uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants an ICS/Long-acting beta2-agonist (LABA).

Important Limitation of Use: AirDuo Digihaler is NOT indicated for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

Important safety information

  • Contraindications: ArmonAir Digihaler and AirDuo Digihaler are contraindicated in:
    • Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
    • Patients with known severe hypersensitivity to milk proteins or any ingredients of ArmonAir Digihaler or AirDuo Digihaler
  • Serious Asthma-Related Events – Hospitalizations, Intubations, Death: Use of AirDuo Digihaler, LABA as monotherapy (ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone
  • Deterioration of Disease and Acute Episodes: AirDuo Digihaler should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta2-agonist, not ArmonAir Digihaler or AirDuo Digihaler, should be used to relieve acute symptoms such as shortness of breath
  • Excessive Use and Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason
  • Local Effects of ICS: Oropharyngeal candidiasis has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation
  • Immunosuppression: Patients who use corticosteroids, such as found in AirDuo Digihaler and ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections
  • Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS. Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler or AirDuo Digihaler
  • Hypercorticism and Adrenal Suppression may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler or AirDuo Digihaler slowly
  • Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors: The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler or AirDuo Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur; increased cardiovascular adverse effects may also occur with AirDuo Digihaler
  • Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. If bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue AirDuo Digihaler or ArmonAir Digihaler and institute alternative therapy
  • Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler or AirDuo Digihaler. Discontinue ArmonAir Digihaler or AirDuo Digihaler if such reactions occur
  • Cardiovascular and Central Nervous System Effects: The salmeterol component of AirDuo Digihaler, can be associated with excessive beta-adrenergic stimulation which could present as the following symptoms: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Use with caution in patients with cardiac arrhythmias, hypertension, coronary insufficiency. Drug may need to be discontinued in certain patients.
  • Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler or AirDuo Digihaler
  • Effect on Growth: ICS may cause a reduction in growth velocity. Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler and AirDuo Digihaler.
  • Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler and AirDuo Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered
  • Eosinophilic Conditions and Churg‑Strauss Syndrome: Systemic eosinophilic conditions, such as Churg-Strauss syndrome, may occur when using ArmonAir Digihaler or AirDuo Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy
  • Coexisting Conditions: Use AirDuo Digihaler with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines
  • Hypokalemia and Hyperglycemia: Beta‑adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. Decreases in serum potassium are usually transient, not requiring supplementation. Be alert to hypokalemia and hyperglycemia in patients using AirDuo Digihaler
  • Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (reported in greater than or equal to 3% of subjects) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough
  • Adverse Reactions with AirDuo Digihaler: Most common adverse reactions (reported in greater than or equal to 3% of patients) include nasopharyngitis, oral candidiasis, headache, cough and back pain

Please see full Prescribing Information for AirDuo Digihaler and ArmonAir Digihaler.

 

Devices comply with part 15 of the FCC Rules. Operation is subject to the following two conditions: (1) These devices may not cause harmful interference, and (2) these devices must accept any interference received, including interference that may cause undesired operation. Changes or modifications not expressly approved by Teva could void the user’s authority to operate the equipment.